LC
ADAP

Lindbrook Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Lindbrook Capital’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$908 Hold
4,610
– – ﹤0.01% 2489
2024
Q4 		$2.48K Sell
4,610
-237
-5% -$173 ﹤0.01% 2242
2024
Q3 		$4.61K Buy
4,847
+237
+5% +$269 ﹤0.01% 2044
2024
Q2 		$4.49K Sell
4,610
-2,135
-32% -$2.34K ﹤0.01% 2048
2024
Q1 		$10.7K Buy
6,745
+2,135
+46% +$2.58K ﹤0.01% 1537
2023
Q4 		$3.66K Hold
4,610
– – ﹤0.01% 2041
2023
Q3 		$3.6K Hold
4,610
– – ﹤0.01% 1916
2023
Q2 		$4.26K Buy
+4,610
New +$5.5K ﹤0.01% 1884
2022
Q4 		– Sell
-3,084
Closed -$3K – 2824
2022
Q3 		$3K Buy
3,084
+2,766
+870% +$5.08K ﹤0.01% 1825
2022
Q2 		$1K Buy
318
+139
+78% +$239 ﹤0.01% 2125
2022
Q1 		$0 Sell
179
-3,096
-95% -$8.36K ﹤0.01% 2461
2021
Q4 		$12K Sell
3,275
-5,392
-62% -$24.5K ﹤0.01% 1187
2021
Q3 		$45K Buy
8,667
+2,057
+31% +$9.23K 0.01% 462
2021
Q2 		$28K Buy
6,610
+5,000
+311% +$24.3K 0.01% 657
2021
Q1 		$9K Hold
1,610
– – ﹤0.01% 1041
2020
Q4 		$9K Hold
1,610
– – ﹤0.01% 932
2020
Q3 		$13K Sell
1,610
-2,448
-60% -$21.4K ﹤0.01% 745
2020
Q2 		$41K Buy
4,058
+3,120
+333% +$19.6K 0.01% 409
2020
Q1 		$3K Buy
+938
New +$3.11K ﹤0.01% 1150

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lindbrook Capital's ADAP Position: Q1 2025 in Review

Lindbrook Capital held its Adaptimmune Therapeutics (ADAP) position steady in Q1 2025 at 4,610 shares worth $908. The position accounts for ﹤0.01% of the portfolio, ranked #2489.

Lindbrook Capital first reported a position in ADAP in Q1 2020 and has held it in 19 quarters since. The position peaked at $45K in Q3 2021. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Lindbrook Capital held 4,610 shares of Adaptimmune Therapeutics worth $908 as of Q1 2025.
  • Lindbrook Capital left its Adaptimmune Therapeutics share count unchanged in Q1 2025.
  • Adaptimmune Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2489 holding.
  • Lindbrook Capital first reported a position in Adaptimmune Therapeutics in Q1 2020 and has held it in 19 quarters since.
  • Lindbrook Capital's Adaptimmune Therapeutics position peaked at $45K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.